Combination therapy with Ixabepilone Plus Capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to Anthracyclines and Taxanes

Introduction: ER/PR/HER2-negative BC patients have fewer treatment options than those with receptor-positive tumors. Ixabepilone showed activity in phase 2 studies of anthracycline- and taxane-pretreated metastatic breast cancer (MBC), including ER/PR/HER2-negative disease. Methods: In 752 patients with anthracycline/taxane-resistant MBC, ixabepilone, 40mg/m2 IV over 3h q3wk, in combination with capecitabine, 2000mg/m2 PO d1-d14 q3wk, was compared with capecitabine alone, 2.500mg/m2 on the same schedule. PFS and ORR were prospectively analyzed for the ER/PR/HER2-negative patient subgroup (25%) and compared to th…